PHOENIX – Patients who have nasal polyps appeared to get symptom relief when treated with omalizumab (Xolair) regardless of comorbid asthma, according to a post-hoc trial analysis. All patients taking ...

Nasal polyps are soft, noncancerous growths on the lining of the nose or sinuses. These growths, while painless, can cause blockages that prevent the sinuses from draining properly. This can make it ...

Please provide your email address to receive an email when new articles are posted on . Three currently available type 2 biologics approved for asthma appeared effective in treating chronic ...

For severe chronic rhinosinusitis with nasal polyps, the novel monoclonal antibody stapokibart reduced symptoms and polyp size atop treatment with a daily intranasal corticosteroid. The polyp size ...

Nasal polyp development, treatment, and recurrence were topics up for discussion in this year’s most popular nasal polyps–related content. Nasal polyp development, treatment, and recurrence, as well ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Prevalence of type 2 inflammation ranged from 64.2% to ...

A comparison of type 2 biologics indicated for the treatment of chronic rhinosinusitis with nasal polyps identified dupilumab as the most effective drug in decreasing nasal polyp score and nasal ...

Competition among biologics that target inflammatory respiratory disease is heating up even further. On Thursday, AstraZeneca said its Fasenra, used in tandem with standard steroids, significantly ...

Nasal polyps are common, affecting up to 4% of the general population, and can affect quality of life, but are usually benign. However, a new study suggests that when they occur in older patients (≥ ...

Dublin, Oct. 22, 2025 (GLOBE NEWSWIRE) -- The "Nasal Polyps - Pipeline Insight, 2025" has been added to ResearchAndMarkets.com's offering. The Nasal Polyps - Pipeline Insight, 2025 report offers ...